Wockhardt Eyes US Biosimilars In Wake Of Reddy’s Deal
Divestment Will Provide Liquidity To Bolster International Operations
India’s Wockhardt says that developing biosimilars for the US will be one of its strategic priorities after the divestment of parts of its branded generics business to Dr Reddy’s unlocks “adequate liquidity for robust growth in international operations.” The firm remains upbeat about its future prospects despite its annual results revealing a widespread sales slump, albeit coupled with a recovery in profitability.
